Abstract：
OBJECTIVE: This study sought to provide an overview of the current research and further analyze publication trends in the field of vascular endothelial growth factor (VEGF) and anti-VEGF treatment for neovascular age-related macular degeneration (NVAMD).
METHODS: We downloaded all related publications from 2001 to 2020 from the Web of Science Core Collection and conducted a bibliometric analysis using the bibiometrix package in R programming software.
RESULTS: A total of 3717 publications were included in the analysis. The USA contributed the largest number of publications (1443), and achieved the highest number of citations (74,946) and H-index value (28). Johns Hopkins University, USA, was the top institution with the most publications, and Peter A. Campochiaro was the most productive professor at The Wilmer Eye Institute, USA. 9.60% of the total publications were from the Journal of Retinal and Vitreous Diseases. Trend analysis demonstrated that anti-VEGF therapy was introduced in early 2000 after steroids, and the last 2 decades have witnessed the blossom of several anti-VEGF agents. \"Treat-and-extend\" and \"resistance\" were two popular trend topics in recent years.
CONCLUSIONS: The USA occupies a dominant position in the research field of VEGF and anti-VEGF treatments in NVAMD. Steroid administration, photodynamic therapy, and anti-VEGF therapy have been pivotal advances in the treatment of NVAMD patients over the past 2 decades. Limited acting period and resistance are potential investigation directions in future studies.
METHODS: We downloaded all related publications from 2001 to 2020 from the Web of Science Core Collection and conducted a bibliometric analysis using the bibiometrix package in R programming software.
RESULTS: A total of 3717 publications were included in the analysis. The USA contributed the largest number of publications (1443), and achieved the highest number of citations (74,946) and H-index value (28). Johns Hopkins University, USA, was the top institution with the most publications, and Peter A. Campochiaro was the most productive professor at The Wilmer Eye Institute, USA. 9.60% of the total publications were from the Journal of Retinal and Vitreous Diseases. Trend analysis demonstrated that anti-VEGF therapy was introduced in early 2000 after steroids, and the last 2 decades have witnessed the blossom of several anti-VEGF agents. \"Treat-and-extend\" and \"resistance\" were two popular trend topics in recent years.
CONCLUSIONS: The USA occupies a dominant position in the research field of VEGF and anti-VEGF treatments in NVAMD. Steroid administration, photodynamic therapy, and anti-VEGF therapy have been pivotal advances in the treatment of NVAMD patients over the past 2 decades. Limited acting period and resistance are potential investigation directions in future studies.
摘要：
目的：本研究旨在提供当前研究的概述，并进一步分析血管内皮生长因子（VEGF）和抗VEGF治疗新生血管性年龄相关性黄斑变性（NVAMD）领域的发表趋势。
方法：我们从WebofScienceCoreCollection下载了2001年至2020年的所有相关出版物，并使用R编程软件中的bibibiometrix软件包进行了文献计量分析。
结果：共3717篇出版物被纳入分析。美国贡献了最多的出版物（1443），并获得了最高的引用次数(74,946次)和H指数值(28次)。约翰霍普金斯大学,美国,是拥有最多出版物的顶级机构，PeterA.Campochiaro是Wilmer眼科研究所最有成效的教授,美国。总出版物的9.60％来自《视网膜和玻璃体疾病杂志》。趋势分析表明，抗VEGF治疗是在2000年初引入类固醇治疗后，在过去的20年里，见证了几种抗VEGF药物的开花。“治疗和扩展”和“抵抗”是近年来流行的两个趋势话题。
结论：在NVAMD中VEGF和抗VEGF治疗的研究领域中，美国占据主导地位。类固醇给药,光动力疗法,在过去的20年中,抗VEGF治疗在NVAMD患者的治疗中取得了重要进展。有限的作用期和耐药性是未来研究的潜在研究方向。
方法：我们从WebofScienceCoreCollection下载了2001年至2020年的所有相关出版物，并使用R编程软件中的bibibiometrix软件包进行了文献计量分析。
结果：共3717篇出版物被纳入分析。美国贡献了最多的出版物（1443），并获得了最高的引用次数(74,946次)和H指数值(28次)。约翰霍普金斯大学,美国,是拥有最多出版物的顶级机构，PeterA.Campochiaro是Wilmer眼科研究所最有成效的教授,美国。总出版物的9.60％来自《视网膜和玻璃体疾病杂志》。趋势分析表明，抗VEGF治疗是在2000年初引入类固醇治疗后，在过去的20年里，见证了几种抗VEGF药物的开花。“治疗和扩展”和“抵抗”是近年来流行的两个趋势话题。
结论：在NVAMD中VEGF和抗VEGF治疗的研究领域中，美国占据主导地位。类固醇给药,光动力疗法,在过去的20年中,抗VEGF治疗在NVAMD患者的治疗中取得了重要进展。有限的作用期和耐药性是未来研究的潜在研究方向。
